 Long-term follow-up prognostic factor analysis advanced ovarian carcinoma Gynecologic Oncology Group experience Long-term follow-up women advanced ovarian carcinoma suboptimal stage III IV primary chemotherapy Gynecologic Oncology Group GOG first study melphalan versus melphalan hexamethylmelamine versus cyclophosphamide doxorubicin CA second study CA regimen cisplatin Eligibility studies last contact patients alive multivariate analysis cell type clear cell mucinous cisplatin-based treatment good performance status age stage nonmeasurable disease residual tumor volume absence ascites favorable characteristics overall survival Second-look laparotomy negative endometrioid tumors negative second-look laparotomies mucinous clear cell tumors patients suboptimal stage III disease negative second-look laparotomy recurrence cisplatin treatment beneficial new treatments